I de kliniske undersøgelser var de behandlingsrelaterede bivirkninger imidlertid numerisk hyppigere i Xeomin- gruppen end i Botox- gruppen.
9 However, in clinical trials the related adverse events were numerically more frequent in the Xeomin group compared to the Botox group.